Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations

Journal of Thoracic Oncology

Volumn 9, Issue 6, 2014, Pages 805-811

  Haaland, Benjamin ^a,b   Tan, Pui San ^a   De Castro, Gilberto ^c   Lopes, Gilberto ^c,d  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Epidermal growth factor receptor activating mutations; Meta analysis; Non small cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

AFATINIB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; DIARRHEA; DISEASE CONTROL; DRY SKIN; FATIGUE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; VOMITING; CARCINOMA, NON-SMALL-CELL LUNG; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GENETICS; LUNG NEOPLASMS; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84901621715     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000156     Document Type: Article

References (34)

1. GLOBOCAN 2008: Country Fast Stat. Available at: http://globocan.iarc. fr/factsheet.asp.
2. Navada S, Lai P, Schwartz AG, Kalemkerian GP. Temporal trends in small cell lung cancer: Analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database. J Clin Oncol 2006; 24(18 Suppl): 7082. Available at: http://meeting.ascopubs.org/cgi/content/abstract/24/18-suppl/7082.
3. Barlesi F, Blons H, Beau-Faller M, et al. Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts). Proc ASCO Annual Meeting 2013;13:abstract 8000.
4. Kris MG, Johnson BE, Kwiatkowski DJ, et al. "Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC)." J Clin Oncol 2011;29:abstract CRA7506.
5. Rosell R, Moran T, Queralt C, et al; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
6. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500. (Pubitemid 38720929)
7. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
8. Suda K, Mizuuchi H, Maehara Y, et al. "Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny." Cancer Metastasis Rev 2012;31:807-814.
9. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-354. (Pubitemid 40637826)
10. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-4711.
11. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
12. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first- line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-2874.
13. Mitsudomi T, Morita S, Yatabe Y, et al; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
14. Maemondo M, Inoue A, Kobayashi K, et al; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
15. Inoue A, Kobayashi K, Maemondo M, et al. "Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin- paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)." Ann Oncol 2013;24:54-59.
16. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012;30:1122-1128.
17. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutation-positive non- small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
18. Zhou C, Wu YL, Liu X, et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30(Suppl): abstract 7520. Available at: [http://meeting.ascopubs. org/cgi/content/abstract/30/15-suppl/7520?sid=a5cc620f-0c43- 44c6-8657-7e9c02900e62]
19. Rosell R, Carcereny E, Gervais R, et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
20. Sequist LV, Yang JC, Yamamoto N, et al. "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations." J Clin Oncol 2013;31: 3327-3334.
21. Wu YL, Zhou C, Hu CP, et al. LUX-Lung 6: A randomized, openlabel, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first- line treatment for Asian patients (pts) with EGFR mutationpositive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol 2013;31:8016. Available at: http://meeting.ascopubs.org/cgi/content/abstract/31/15-suppl/8016?sid= 10a00426-0aa0-41db-b92ee651abbb5f83.
22. ASCO Meeting Library. Available at: http://meetinglibrary.asco.org/ search/site.
23. European Cancer Congress 2013. Available at: http://eccamsterdam2013. ecco-org.eu/Scientific-Programme/Searchable-Programme.aspx.
24. Chinese Clinical Trial Registry. Available at: http://www.chictr.org/en/.
25. ClinicalTrials.gov. Available at: clinicaltrials.gov.
26. EU Clinical Trials Register. Available at: https://www. clinicaltrialsregister. eu.
27. UMIN Clinical Trials Registry. Available at: http://www.umin.ac.jp/ctr/.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188. (Pubitemid 17189972)
29. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558. (Pubitemid 34746062)
30. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105:2070-2075. (Pubitemid 351439466)
31. Mills EJ, Thorlund K, Ioannidis JP. "Demystifying trial networks and network meta-analysis." BMJ 2013;346:f2914.
32. Cochrane Handbook, Higgins, and Green. "Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Updated March 2011]." The Cochrane Collaboration, 2011.
33. Lumley T. "Network meta-analysis for indirect treatment comparisons." Stat Med 2002; 21: 2313-2324.
34. LUX-Lung 7: A Phase IIb Trial of Afatinib (BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung-ClinicalTrials.gov. Available at: http://clinicaltrials.gov/show/ NCT01466660.